Izalontamab (SI-B001), a novel EGFR/HER3 bispecific monoclonal antibody, was well-tolerated and exhibited preliminary antitumor activity in previously treated patients with locally advanced or metastatic epithelial tumors, according to results…
First-in-Human Data Support Izalontamab in Advanced Epithelial Tumors | Targeted Oncology
